202 related articles for article (PubMed ID: 30203445)
21. Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.
Booth L; Albers T; Roberts JL; Tavallai M; Poklepovic A; Lebedyeva IO; Dent P
Oncotarget; 2016 Jun; 7(26):40398-40417. PubMed ID: 27259258
[TBL] [Abstract][Full Text] [Related]
22. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2019; 9():650. PubMed ID: 31380285
[TBL] [Abstract][Full Text] [Related]
23. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
Dent P; Booth L; Poklepovic A; Hoff DV; Hancock JF
Cell Signal; 2020 Apr; 68():109525. PubMed ID: 31911180
[TBL] [Abstract][Full Text] [Related]
24. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
[TBL] [Abstract][Full Text] [Related]
25. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Sajithlal GB; Hamed HA; Cruickshanks N; Booth L; Tavallai S; Syed J; Grant S; Poklepovic A; Dent P
Mol Pharmacol; 2013 Oct; 84(4):562-71. PubMed ID: 23877009
[TBL] [Abstract][Full Text] [Related]
27. Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.
Dent P; Booth L; Poklepovic A; Martinez J; Hoff DV; Hancock JF
J Cell Physiol; 2020 Nov; 235(11):7889-7899. PubMed ID: 31912905
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.
Booth L; Roberts JL; Cruickshanks N; Conley A; Durrant DE; Das A; Fisher PB; Kukreja RC; Grant S; Poklepovic A; Dent P
Mol Pharmacol; 2014 Mar; 85(3):408-19. PubMed ID: 24353313
[TBL] [Abstract][Full Text] [Related]
29. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Booth L; Poklepovic A; Dent P
Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
[TBL] [Abstract][Full Text] [Related]
30. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
[TBL] [Abstract][Full Text] [Related]
31. Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
Webb T; Carter J; Roberts JL; Poklepovic A; McGuire WP; Booth L; Dent P
Cancer Biol Ther; 2015; 16(11):1660-70. PubMed ID: 26417912
[TBL] [Abstract][Full Text] [Related]
32. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
Chen D; Wei L; Yu J; Zhang L
Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
[TBL] [Abstract][Full Text] [Related]
34. PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells.
Roberts JL; Booth L; Conley A; Cruickshanks N; Malkin M; Kukreja RC; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2014 Jun; 15(6):758-67. PubMed ID: 24651037
[TBL] [Abstract][Full Text] [Related]
35. Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib.
Wu CS; Wu SY; Chen HC; Chu CA; Tang HH; Liu HS; Hong YR; Huang CF; Huang GC; Su CL
J Nutr Biochem; 2019 Dec; 74():108227. PubMed ID: 31675556
[TBL] [Abstract][Full Text] [Related]
36. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
[TBL] [Abstract][Full Text] [Related]
37. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
[TBL] [Abstract][Full Text] [Related]
38. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
[TBL] [Abstract][Full Text] [Related]
39. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
Wang YJ; Zhang YK; Zhang GN; Al Rihani SB; Wei MN; Gupta P; Zhang XY; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2017 Jun; 396():145-154. PubMed ID: 28302530
[TBL] [Abstract][Full Text] [Related]
40. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
